Difference between revisions of "MAPT-AS1"
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
===Chromosome=== | ===Chromosome=== | ||
17q21.31 | 17q21.31 | ||
| − | [[File: Effect of MAPT-AS1 over- and knock-down expression on MAPT expression in HEK293 and SK-N-MC cells.jpg|right|thumb|400px|'''Effect of MAPT-AS1 over- and knock-down expression on MAPT expression in HEK293 and SK-N-MC cells.''' <ref name=" | + | [[File: Effect of MAPT-AS1 over- and knock-down expression on MAPT expression in HEK293 and SK-N-MC cells.jpg|right|thumb|400px|'''Effect of MAPT-AS1 over- and knock-down expression on MAPT expression in HEK293 and SK-N-MC cells.''' <ref name="ref2" />.]] |
===RefSeq(supplied by NCBI)=== | ===RefSeq(supplied by NCBI)=== | ||
NR_024559 | NR_024559 | ||
| Line 10: | Line 10: | ||
MAPT-AS1 is an 840 bp lncRNA transcribed from the anti-sense strand of the MAPT promoter region.<ref name="ref1" /> | MAPT-AS1 is an 840 bp lncRNA transcribed from the anti-sense strand of the MAPT promoter region.<ref name="ref1" /> | ||
===Expression=== | ===Expression=== | ||
| − | The siRNA s237111 can | + | The siRNA s237111 can knock-down the expression of MAPT-AS1.The sequence of the s237111 siRNA is described in the table below.<ref name="ref2" /> |
{| class='wikitable' style="text-align:center" | {| class='wikitable' style="text-align:center" | ||
|- | |- | ||
| Line 19: | Line 19: | ||
| | 5’-UUACUUAUCCAUGAAGUGGgt-3’<ref name="ref2" /> | | | 5’-UUACUUAUCCAUGAAGUGGgt-3’<ref name="ref2" /> | ||
|} | |} | ||
| + | ===Function=== | ||
| + | MAPT-AS1 has an inhibitory effect on the expression of a major neurodegenerative gene, MAPT. MAPT-AS1 may serve as a sensitive biomarker of disease state in Parkinson’s disease, as well as a potential therapeutic target for inhibiting the expression of MAPT. <ref name="ref2" /> | ||
| + | ==Labs working on this lncRNA== | ||
| + | * Genomics Institute, University of California Santa Cruz, Santa Cruz, CA 95064, USA.<ref name="ref1" /> | ||
| + | * Neuroscience Research Australia, Randwick, NSW, Australia.<ref name="ref2" /> | ||
| + | * School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.<ref name="ref2" /> | ||
| + | ==References== | ||
| + | <references> | ||
| + | <ref name="ref1"> Speir, M.L., et al., The UCSC Genome Browser database: 2016 update. Nucleic Acids Res, 2016. 44(D1): p. D717-25. | ||
| + | </ref>(1) | ||
| + | <ref name="ref2">Coupland, K.G., et al., Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease. PLoS One, 2016. 11(6): p. e0157924. | ||
| + | </references> | ||
Latest revision as of 14:55, 22 October 2017
Contents
Annotated Information
Approved Symbol
MAPT-AS1 (MAPT antisense RNA 1)
Chromosome
17q21.31
Effect of MAPT-AS1 over- and knock-down expression on MAPT expression in HEK293 and SK-N-MC cells. [1].
RefSeq(supplied by NCBI)
NR_024559
Characteristics
MAPT-AS1 is an 840 bp lncRNA transcribed from the anti-sense strand of the MAPT promoter region.[2]
Expression
The siRNA s237111 can knock-down the expression of MAPT-AS1.The sequence of the s237111 siRNA is described in the table below.[1]
| sense | antisense |
|---|---|
| 5’-CCACUUCAUGGAUAAGUAAtt-3’ | 5’-UUACUUAUCCAUGAAGUGGgt-3’[1] |
Function
MAPT-AS1 has an inhibitory effect on the expression of a major neurodegenerative gene, MAPT. MAPT-AS1 may serve as a sensitive biomarker of disease state in Parkinson’s disease, as well as a potential therapeutic target for inhibiting the expression of MAPT. [1]
Labs working on this lncRNA
- Genomics Institute, University of California Santa Cruz, Santa Cruz, CA 95064, USA.[2]
- Neuroscience Research Australia, Randwick, NSW, Australia.[1]
- School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.[1]
